



Recent Advances in Immunotherapy of Multiple Myeloma

Guest Editor:

Dr. Catarina Geraldes

1. Laboratory of Oncobiology and Hematology (LOH), University Clinic of Hematology, Faculty of Medicine (FMUC), University of Coimbra, 3000-548 Coimbra, Portugal

2. Coimbra Institute for Clinical and Biomedical Research (iCBR) —Group of Environmental Genetics of Oncobiology (CIMAGO), FMUC, University of Coimbra, 3000-548 Coimbra, Portugal

3. Hematology Service, Centro Hospitalar e Universitário de Coimbra (CHUC), 3000-061 Coimbra, Portugal

Deadline for manuscript submissions:

closed (20 March 2024)

Message from the Guest Editor

Dear Colleagues,

In the last few years, there have been remarkable advances in the knowledge of the molecular and cellular mechanisms involved in multiple myeloma (MM) development and progression, leading to new therapies, particularly in the field of immunotherapy. Some of these advances are related to immunomodulatory drugs (IMiDs). Additionally, they relate to monoclonal antibodies (mAbs), targeting specific proteins on the surface of myeloma cells. Chimeric antigen receptor (CAR) T cell therapy uses patient's own genetically modified T cells to recognize specific antigen on cancer cells and has received FDA and EMA approval for the treatment of RRMM.

This Special Issue aims to publish current research related to the discovery of novel biomarkers and targets for immunotherapies in MM as well as the mechanism related with resistance to this kind of therapy. Original research articles and review articles covering these knowledge fields are strongly invited, including: cellular and molecular mechanisms; genomic, proteomic, and metabolic profiles; biomarkers of prognosis; therapy monitoring; and drug response and resistance.

Dr. Catarina Geraldes

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Maurizio Battino

Department of
Odontostomatologic and
Specialized Clinical Sciences,
Sez-Biochimica, Faculty of
Medicine, Università Politecnica
delle Marche, Via Ranieri 65,
60100 Ancona, Italy

Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Inorganic Chemistry)

Contact Us

*International Journal of Molecular
Sciences* Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/ijms
ijms@mdpi.com
X@IJMS_MDPI